Rizwana F. Sproule, VP Regulatory Affairs at Kite Pharma, Inc. (KITE), sold 9,567 shares at $64.08 ($599K) on 2015-10-15, disclosed to the SEC on 2015-10-19.
Scheduled sale ($599k) by VP Regulatory Affairs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $60.36 | 395 | $24K | 4.0% |
| 2 | $61.54 | 1,442 | $89K | 14.8% |
| 3 | $62.41 | 4,377 | $273K | 45.6% |
| 4 | $63.32 | 2,475 | $157K | 26.2% |
| 5 | $64.08 | 878 | $56K | 9.4% |
| Total | $62.58 avg | 9,567 |
| $599K |
| 100% |
| Filing → |
| KITE | SELL | 2016-01-19 | $531K | — | Filing → |
| KITE | SELL | 2015-12-17 | $610K | — | Filing → |
| KITE | SELL | 2015-11-18 | $748K | — | Filing → |